ADC Therapeutics SA — Form 6-K Summary
Business context and reporting period
ADC Therapeutics SA, a Swiss biopharmaceutical company, furnished this Form 6-K for March 2023. The filing relates to the company’s 2022 Annual Report and the Compensation Report for the year ended December 31, 2022.
Financial and operating metrics
The provided filing text does not include clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash balances, or other operating metrics. These items may be contained in Exhibit 99.1, identified as the “2022 Annual Report,” but the exhibit content is not included in the source text.
Material changes versus the prior comparable period
The filing text does not provide financial or operating comparisons with the prior period.
Guidance, outlook, risks, contingencies, and unusual items
The filing does not provide guidance, outlook, risk disclosures, contingencies, or unusual-item details in the supplied text.
Sections covering compensation of the Board of Directors and executive management in the 2022 Compensation Report are incorporated by reference into the company’s Form F-3 registration statements Nos. 333-267293 and 333-267295, to the extent not superseded by later filings.
Investor verification points
- Review Exhibit 99.1 for the complete 2022 Annual Report and underlying financial statements.
- Verify 2022 revenue, operating loss, net loss, cash flow, cash and restricted cash, debt, and liquidity runway.
- Review management’s discussion of product performance, pipeline developments, clinical and regulatory risks, and going-concern or financing considerations.
- Review the compensation disclosures incorporated by reference into the Form F-3 registration statements.